Cyprotex extends ties with Pfizer

Cyprotex, the pharmaceuticals company specialising in the adverse effects of chemicals on living organisms, has signed a collaborative research agreement with US pharmaceuticals giant Pfizer.

The two parties will evaluate, further develop, and improve several of Cyprotex's proprietary offerings in the area of predictive toxicology.

The deal extends over an eighteen month period and is split into two stages with the second stage being dependent on certain milestones being achieved.

Try 6 free issues of MoneyWeek today

Get unparalleled financial insight, analysis and expert opinion you can profit from.

Start your trial

Sign up for MoneyWeek’s free twice-daily newsletter.

Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.

Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.

Sign up

"This collaborative research is beneficial for both companies and allows Cyprotex to remain at the forefront of new approaches in toxicology prediction. Predicting drug-induced toxicity is a challenging field, and we are making significant advances by combining our knowledge with that of our partners and clients," said Dr Anthony Baxter, Cyprotex's Chief Executive Officer.